Background: In mdx mice, the absence of dystrophin leads to the deficiency of other components of the dystrophinglycoprotein complex (DAPC), making skeletal muscle fibers more susceptible to necrosis. The mechanisms involved in the disappearance of the DAPC are not completely understood. The muscles of mdx mice express normal amounts of mRNA for the DAPC components, thus suggesting post-transcriptional regulation.
Introduction
Dystrophin is a cytoplasmic protein belonging to a large oligomeric complex (dystrophin-associated protein complex, or DAPC) that associates with other proteins, including sarcoglycans, syntrophins, dystroglycans, syntrobrevin, and sarcospan [1] [2] [3] . The DAPC plays an important structural role in linking the actin cytoskeleton to the extracellular matrix. A disruption of the DAPC impairs muscle fiber function; therefore, several myopathies are due to genetic defects found in the DAPC proteins [3] [4] [5] [6] [7] [8] [9] [10] [11] . The most common myopathies caused by a defect in the DAPC complex are Duchenne Muscular Dystrophy (DMD) and its milder form, Becker Muscular Dystrophy, which are both caused by mutations in the X2linked dystrophin gene [4] [5] [6] . Defects in sarcoglycan (SG) subunits are associated with an autosomal recessive form of Limb Girdle Muscular Dystrophy [7, 8] . Although no human diseases have been found to result from mutations in the dystroglycan gene, impaired glycosylation of the a-dystroglycan subunit due to defects in glycosyltransferases leads to muscular disorders [9, 10] . A deficiency of the syntrophindystrobrevin subcomplex has been observed in patients with inherited myopathy [11] .
Different animal models are available to study the different dystrophies. The most commonly used laboratory animal model of DMD is the mdx mouse. In these animals, all the muscles lack dystrophin, however, mdx mice show a much milder phenotype than DMD patients [12] . Although the muscles of mdx mice are affected to a different extent, physical exercise worsens the pathology, similar to that observed in the human disease [13] . Genetically modified animal models that are deficient in the four different SG subunits have also been developed, and their phenotype is associated with skeletal and cardiac myopathies [14] [15] [16] [17] [18] .
Studies using these animal models of different myopathies revealed that the DAPC is tightly regulated. A deletion or mutation in the gene of one of the components of the DAPC leads to destabilization of the entire complex and a strong reduction in the intracellular concentration of the other proteins [14] [15] [16] [17] [18] [19] . The mechanisms involved in this phenomenon are not yet completely understood. Because treatment with proteasome inhibitors, have been shown to promote upregulation of the expression levels of some members of the DAPC in mdx mice and in the muscular explants obtained from patients with DMD or BMD, it has been suggested that the degradation system is involved in inhibiting DAPC proteins expression in dystrophy [20] [21] [22] .
In recent years, mounting evidence has shown the pivotal role of small, non-coding RNAs, such as microRNAs (miRs), in the negative regulation of gene expression [23] [24] [25] . In the nucleus, miRs are transcribed as long primary transcripts (pri-miRs) and processed into 60-120 nucleotide hairpin precursors (pre-miRs), which are exported to the cytoplasm where they are further processed into mature 21-23 nucleotide transcripts. One of the two strands of the mature microRNAs is incorporated into the large protein complex, RISC (RNA-Induced Silencing Complex), and guides the complex to the target mRNA. MicroRNA modulation of gene expression can occur by blocking translation or by cleavage and degradation of the target mRNA [23] [24] [25] . Several miRs (miR-1, miR-133, and miR-206) have been shown to be specifically expressed in the skeletal muscle [26] [27] [28] [29] [30] [31] [32] . These miRs could play a role in numerous muscular diseases, as microarray analysis of muscle samples obtained from patients affected by different muscular disorders, including DMD and BMD, revealed that approximately 200 miRs were differentially expressed [30, 31] . Among these miRs, five (miR-146b, miR-221, miR-155, miR-214, and miR-222) were found to be consistently dysregulated in the different analyzed diseases [31] . In a recent study, Greco et al. [32] reported the detection of a common miRNA signature in muscles from mdx mice and DMD patients. Here, 11 miRs were found to be dysregulated in both types of samples and were suggested to be involved in the pathways implicated in the response to muscle damage.
To date, no information is available regarding the function of these dysregulated miRs in the different myopathies. We addressed the potential role of miRs in the pathogenesis of DMD, considering that, in muscle tissue obtained from mdx and transgenic mice (a-and b-sarcoglycan knockout mice) normal levels of mRNA for the different components of the DAPC were detected, in spite of the absence of the corresponding proteins, thus ruling out transcriptional regulation of the specific mRNAs [14] [15] [16] [17] [18] [19] . We verified the possible involvement of the microRNA system as a regulator of the DAPC proteins using the mdx mouse model of DMD. We analyzed both mRNA and protein levels of syntrophins and dystroglycans, and focused our study on evaluating the regulation of b1-syntrophin. By analyzing the 39 untranslated region (39UTR) of b1-syntrophin, we found that three miRs could target this protein, and we established that one of these, miR-222, is upregulated in the muscles of mdx mice and is involved in the downregulation of the b1-syntrophin isoform in dystrophic muscles.
Results

RNA and protein expression levels
It has been previously reported that when one of the DAPC components is genetically absent, other proteins of the complex are likewise reduced, and complex formation is ultimately impaired. To confirm this phenomenon, we monitored the mRNA levels, protein expression and immunolocalization of four DAPC components (a-and b-dystroglycan and a, and b1-syntrophin) in different muscles (gastrocnemius, tibialis, extensor digitorum longus, diaphragm) obtained from normal and mdx dystrophic mice.
The dystroglycan gene (Dag) encodes for a single polypeptide that is post-translationally cleaved into two subunits, a-dystroglycan (a-dag) and b-dystroglycan (b-dag) [33] . Using quantitative real time RT-PCR (qRT-PCR), a slight, but not significant decrease in dag mRNA level, was observed in the gastrocnemius muscles of young mdx mice compared to those of wild type (wt) animals. With increasing age, a 50% decrease in dag mRNA level was observed in the dystrophic muscles compared to the muscles of wt adult animals ( Fig. 1) . Although the protein level of the a-dag subunit was not statistically different between muscle tissues from wt and mdx animals of the same age, a-dag was not correctly localized at the sarcolemma of dystrophic muscle cells (Fig. S1A) . The protein level of b-dag tended to decrease in both young and adult muscle tissues from dystrophic mice (Fig. S1B) ; similar to that of the a-subunit, localization of the b-dag protein at the sarcolemma was clearly impaired in the muscle tissues from dystrophic mice (Fig. S1C) . Taken together, these data suggest that a small decrease in a-and b-dystroglycan protein levels occurs in the gastrocnemius muscles of mdx dystrophic animals, probably due to a reduction in Dag gene transcription.
Among the different syntrophin isoforms expressed in skeletal muscle tissues, the a and b1 subunits are preferentially associated with dystrophin and are encoded by two different genes [34] . The mRNA level of the a isoform of syntrophin (a-synt) was slightly increased in the gastrocnemius muscles of mdx mice ( Fig. 2A) . There was no difference in a-syntrophin protein levels between the normal and mdx animals; however, the protein was no longer localized at the plasma membrane of dystrophic muscle fibers, shown by immunofluorescence analysis (Figs. 2B and 2C ). These observations suggest that the absence of a-syntrophin at the cell membrane is probably related to the absence of the entire DAPC but not due to a reduction in its protein levels.
The mRNA level of b1-syntrophin in the muscles of adult mdx mice was almost two-fold higher than that in the gastrocnemius muscles of wt animals (Fig. 3A) . Shown by western blot analysis, a significant reduction in its protein level (approximately 40%), was observed in the muscles of the adult dystrophic mice (Fig. 3B) . Similarly, a reduction of b1-syntrophin protein level was observed when the protein was immunoprecipitated from the whole tissue homogenates of mdx muscles compared to those of wt muscles (Fig. S2 ). As expected, immunofluorescence analysis showed the absence of b1-syntrophin in the plasma membrane of dystrophic skeletal muscle fibers (Fig. 3C) .
The same results were obtained when other types of muscles, such as diaphragm, and extensor digitorum longus were investigated (data not shown), suggesting that a reduction in b1-syntrophin protein level is a general phenomenon.
These data showed that the levels of dystroglycans and asyntrophin were not significantly modified in dystrophic muscles. In contrast, the level of b1-syntrophin was clearly decreased, and this reduction in mdx muscles could not be explained by a decrease in gene transcription. Therefore, our studies focused on post- 
39-UTR analysis
The 39-untranslated regulatory regions (39-UTRs) of mRNAs play an important role in the regulation of mRNA translation. Therefore, we investigated whether the expression of b1-syntrophin was differentially regulated in skeletal muscles between mdx mice and wt mice, and whether this phenomenon was dependent on the 39-UTR of b1-syntrophin. To this end, the 39-UTR of the mRNA encoding b1-syntrophin was cloned into the pEGPF-C1 expression vector, allowing us to assess 39-UTR regulation by examining GFP expression. First, we verified that the construct pEGFP-39-UTR-b1-synt was expressed in transiently transfected COS1 cells, and that introduction of the 39-UTR of b1-syntrophin into the plasmid did not constitutively induce GFP expression (data not shown).
To test the hypothesis that the 39-UTR of b1-syntrophin is differentially regulated in the muscles of dystrophic animals, the pEGFP-39-UTR-b1-synt construct was electroporated into the tibialis anterior muscle of wt and mdx mice. The electroporation procedure induced minimal tissue damage, evaluated by histological observation of the electroporated muscles (data not shown). The results revealed that GFP was consistently detectable in muscle fibers when the empty vector pEGPF-C1, or the pEGFP-39-UTR-b1-synt construct were transfected into the muscles of wt mice (Fig. 4A) , indicating that the 39-UTR of b1-syntrophin does not interfere with GFP expression in skeletal muscles of wt animals. GFP expression was clearly detected in the muscle of mdx mice electroporated with pEGPF-C1; however, the expression was ).
The Ct values of each gene are normalized to the Ct value of GAPDH in the same RNA sample. The mRNA levels in the mdx samples are expressed as fold changes compared to those in wt samples. All values represent the mean 6 SD from three different experiments performed on different RNA preparations of the muscle tissues from wt and mdx mice (see Methods). B: Total protein extracts from the gastrocnemius muscle tissues of wt and mdx mice of the indicated ages were resolved by SDS-PAGE and probed with an a-syntrophin antibody. A representative western blot is shown. The graph values represent the mean 6 SD of the densitometric analyses from three different experiments with different animal samples (see Methods). Data are presented as the percentage of protein in mdx mice compared to that in wt mice, normalized to endogenous actin expression level. C: Frozen sections of the gastrocnemius muscles obtained from wt and mdx adult mice were probed with an anti-a-syntrophin antibody and visualized using a secondary antibody coupled to a fluorescent marker, FITC. A representative of the two performed analyses on two different five-months-old wt and mdx mice, is shown. doi:10.1371/journal.pone.0012098.g002 miR-222 in mdx markedly reduced in the muscles of mdx mice electroporated with pEGFP-39UTR-b1-synt (Fig. 4B ).
These data demonstrated that, in the presence of the b1-syntrophin 3-9UTR, GFP expression was impaired in the muscles of mdx mice, suggesting a differential in vivo regulation of 39-UTRb1-synt between dystrophic muscles and wt muscles.
MicroRNA expression
MicroRNAs are well known regulators of protein expression and their action is mediated by binding to the 3'-UTR of target mRNAs. Since we have just shown that the b1-syntrophin 3'-UTR is negatively regulated in dystrophic muscles, we considered the potential role of microRNAs in the modulation of b1-syntrophin expression. No data are currently available about which specific miRs modulate the expression of DAPC proteins; for this reason, to identify putative miR binding sites on the b1-syntrophin 39-UTR, we took advantage of many computational programs available to predict miRNA targets. We used the target prediction programs, the Miranda package and targetscan, which use microRNAs complementarity to predict target mRNAs. Among the several miRs predicted to bind the b1-syntrophin 39-UTR, three miRs (miR-222, miR-24, and miR-339) were identified by the different databases utilized.
As the first step, we determined whether the three selected miRs were expressed in myogenic cells, such as primary mouse satellite cells and C 2 C 12 cell lines, and in skeletal and heart muscle tissues obtained from five-month-old wt mice. Northern blot analysis revealed that all the three miRs were expressed in pooled samples of skeletal muscle tissues, as well as in proliferating C 2 C 12 myoblasts and differentiated myotubes (data not shown). Next, we investigated whether the differential expression of these miRs ).
The Ct values from each gene are normalized to the Ct value of GAPDH in the same RNA sample. The mRNA levels in the mdx samples are expressed as fold change compared to those in the wt samples. All values represent the mean 6 SD of four experiments performed on different RNA preparations of the muscle tissues from wt and mdx mice (see Method). Statistical significance was determined as *P,0,05 (P = 0,012 as measured by the Mann-Whitney test). B: Total protein extracts from the gastrocnemius muscles of wt and mdx mice were resolved by SDS-PAGE and probed with b1-syntrophin antibodies. A representative western blot is shown. The graph values represent the mean 6 SD of the densitometric analyses from four independent experiments with different animal samples (see Methods). Data are presented as the percentage of protein in mdx mice compared to that in wt mice, normalized to endogenous actin expression level. *P,0,05 versus wt (P = 0,002 as measured by the Mann-Whitney test). C: Sections of the gastrocnemius muscles of wt and mdx adult mice were probed with an anti-b1-syntrophin antibody and visualized using a secondary antibody coupled to a fluorescent marker, FITC. A representative of the two performed analyses on different animals is shown. doi:10.1371/journal.pone.0012098.g003 miR-222 in mdx PLoS ONE | www.plosone.orgoccurred in the muscles of mdx mice compared to those of wt animals. RNA was prepared from wt and mdx skeletal muscle tissues at different ages (20-day, 30-day and five-month-old mice) to follow the disease progression.
Northern blot analysis showed no significant differences in the expression of miR-24 and miR-339 between normal and dystrophic mRNA samples (data not shown). MiR-222 expression was significantly elevated in the gastrocnemius muscles from mdx mice compared to those from wt mice. In particular, a 50% increase in miR-222 levels was observed in the muscles of 20-and 30-day-old mdx mice, and a maximum of three-fold increase was evident in the muscles of five-month-old mdx animals (Fig. 5) .
Thus, these results demonstrate that miR-222 is expressed in skeletal muscles, and notably upregulated in mdx mice, suggesting a potential role of miR-222 in downregulating b1-syntrophin expression in dystrophic muscles.
Analysis of miR-222 responsive elements within the 39-UTR of b1-syntrophin
To determine whether the b1-syntrophin mRNA is the real target of miR-222, the activity of a luciferase reporter construct containing the 39-UTR of b1-syntrophin RNA was evaluated in the presence of miR-222. To perform this experiment, the 39-UTR of b1-syntrophin was cloned into the pGL3 vector, and the construct was transiently transfected into COS1 cells cultured in the absence or presence of different concentrations of miR-222. At the end of the incubation time, the cells were lysed and processed to measure the luciferase activity of the synthesized enzyme. The results showed that luciferase activity was dose-dependently decreased by miR-222 and no luciferase activity was detected when a ''scrambled'' negative control or an anti-miR specific to miR-222 was used in its place (Fig. 6A) . The highest concentration of miR-222 employed (5610 28 M) caused a decrease of 50% in luciferase activity, in agreement with the inhibitory effect observed in other cellular systems by the same miR [35, 36] . This result strongly suggested an interaction between miR-222 and the 39-UTR of b1-syntrophin.
The 39-UTR of b1-syntrophin contains two putative consensus sites for miR-222 binding. To confirm the target specificity of miR-222, two pGL3-39UTR b1-syntrophin constructs, carrying deletions of the complementary sequences that could potentially be involved in the binding of miR-222, were used. Luciferase activity was measured in the cells transfected with the vector mutated in binding site 1 (mut1), or in binding site 2 (mut2), in the presence of 5610 28 M of miR-222. As shown in Fig. 6B , a mutation of binding site 1 almost completely abolished the activity of miR-222, whereas a mutation of binding site 2 only slightly reduced miR-222 activity, indicating that the majority of miR-222 activity is due to the binding to the first consensus sequence.
Functional analysis
As shown by the luciferase activity assays, miR-222 efficiently targeted the 39-UTR of b1-syntrophin. To address the role of miR-222 in regulating b1-syntrophin expression, we investigated the effect of overexpressing or silencing miR-222 on endogenous b1-syntrophin levels in cells. b1-syntrophin is expressed at different levels in several tissues, with the highest expression level observed in the liver [37] . Therefore, to obtain a significant signal, the hepatic cell line, Hep2, was used to assess b1-syntrophin modulation in the presence of exogenous miR-222. The Hep2 cells were transfected with miR-222 and/or anti-miR-222, and b1-syntrophin protein levels were determined by western blot. The results showed that b1-syntrophin expression was reduced by approximately 60% in the hepatic cells transfected with miR-222, and its expression was restored in the cells co-transfected with miR-222 and anti-miR-222 (Fig. 7A ). This result indicates that exogenous miR-222 reduces the protein level of endogenous b1 syntrophin, regardless of the cell origin.
The same experiment was performed in satellite myogenic cells from the muscles of wt and mdx mice. When miR-222 was overexpressed in satellite cells from wt mice, a 40% reduction in b1-syntrophin level was observed; this reduction was abolished when miR-222 activity was blocked by the corresponding antagomir (Fig. 7B) . In the satellite cells from dystrophic muscles of young mice, the expression level of miR-222, measured by qRT-PCR, was 50% higher than that in wt cells (data not shown).
No reduction in b1-syntrophin level in response to exogenous miR-222 was observed in these cells, whereas treatment with antimiR-222 led to a slight increase in b1 syntrophin level, thus counteracting the elevated endogenous level of miR-222 in the mdx muscles (Fig. 7C) . Taken together, these data demonstrate that miR-222 regulates b1-syntrophin protein expression, and silencing miR-222 can restore b1-syntrophin protein expression to normal in dystrophic cells in culture.
Another potential role of miR-222 could be the modulation of other miRs specifically expressed in skeletal muscles. Thus, we investigated whether miR-222 is involved in the expression of three myogenic miRs: miR-1, miR-133 and miR-206. To this end, C 2 C 12 cells were transfected with miR-222 or anti-miR-222. RNA was then extracted and the expression levels of these myogenic miRs were measured by qRT-PCR. The obtained results (Fig. S3) showed that miR-222 regulated the expression of these myogenic miRs: miR-222 overexpression reduced the expression of all these three miRs. Conversely, anti-miR-222 treatment that inhibited endogenous miR-222 exerted no effect on the expression of miR-1, miR-133 and miR-206, probably due to the low miR-222 expression of in C 2 C 12 cells.
Discussion
In this study, we investigated the possible mechanisms regulating the expression of the dystrophin-associated protein complex during the progression of muscular dystrophy. Dystrophin deficiency causes a disruption of the DAPC, with a drastic reduction or loss of its components, and the absence of these proteins in the plasma membrane of muscle cells [14] [15] [16] [17] [18] [19] . The presence of detectable levels of mRNA for the different protein components of the DAPC, and the absence of the corresponding proteins in the muscles of dystrophic mice, suggest the possible involvement of a post-transcriptional mechanism of regulation. While previous papers [20] [21] [22] documented the participation of the proteasome degradation system, our study shows that other mechanisms are involved in the regulation of DAPC, particularly, the microRNA system plays an important role by modulating the translation of the mRNA of some DAPC components.
MiRs are involved in several physiological systems including, skeletal muscles [26] [27] [28] [29] [30] [31] [32] , as well as in numerous diseases. It has recently been reported that miRs are differentially modulated in DMD, suggesting an important role of miRs in this disease [28] [29] [30] [31] [32] . To address the potential mechanistic role of miRs in DMD pathogenesis, we investigated whether miRs are involved in the impaired expression of DAPC components during muscular dystrophy. To this end, we used a well-established animal model of DMD, mdx mice. These mice carry a mutation that results in the absence of dystrophin and, subsequently, leads to a reduction of other DAPC components. In mdx mice, muscle pathology starts at two weeks of age and is characterized by a continuous cycle of degeneration and regeneration of skeletal muscle cells that peaks between three and four weeks of age. After this phase, the disease becomes milder and is characterized by increasing muscular fibrosis that lasts until the late phase of the animals life [38] . Based on this progression pattern of the disease, we analyzed the RNA and protein expression levels of some DAPC components at different stages of the disease. Our results showed that in mdx muscles, the protein level of b1-syntrophin was reduced compared to that in muscles from 30-day-and five-month-old wt mice, whereas, mRNA level of b1-syntrophin increased by 50%. The elevated mRNA level excluded the possibility that a decrease in gene expression was responsible for the protein loss. On the contrary, there was no significant difference in protein and mRNA Figure 5 . miR-222 expression levels in wt and dystrophic skeletal muscle tissues. A: MiR expression was evaluated by northern blot analysis in the gastrocnemius muscle tissues from wt and mdx mice of different ages; U6 levels were used as loading controls. A representative blot from four experiments is shown. B: Northern blot signals were quantified by densitometric analysis. The graph shows the mean 6 SD from four independent experiments. For each experiment, pooled muscle tissues were used (see Methods). The miR-222 levels in dystrophic samples are expressed as fold change relative to those in control samples. Statistical significance was determined as *P,0,05 versus wt (P = 0,024 measured by the Mann-Whitney test). doi:10.1371/journal.pone.0012098.g005 levels of a-syntrophin, and a-and b-dystroglycan between normal and dystrophic muscles; however, all these proteins were clearly absent in the cell membrane of dystrophic muscles, suggesting that this absence is not due to a block in mRNA translation but more likely due to impaired localization.
Based on these results, our studies focused on the potential posttranscriptional mechanisms that might be involved in b1-syntrophin regulation in dystrophic muscle tissues. In vivo experiments confirmed that the absence of b1-syntrophin in muscles from mdx mice was due to a block in translation. After pEGFP-39-UTR-b1-synt was electroporated into the posterior limb muscle of wt and mdx mice, histological analysis revealed that GFP was clearly expressed in wt muscles, but only at a very low level in mdx muscles, demonstrating a specific modulation of the 39-UTR. By analyzing this 39-UTR, we identified putative consensus binding sites for three miRs: miR-24, miR-222 and miR-339. All of these miRs were expressed in skeletal muscle tissues of wt and dystrophic mice. MiR-222 level was higher in dystrophic muscles compared to that in wt muscles, and the levels increased with the progression of the disease. MiR-222 was also the only miR specifically binding the 39-UTR of the b1-syntrophin mRNA. MiR-222 expression was also detectable in primary satellite cell cultures and was 50% higher in myogenic cells from young mdx mice compared to that in wt cells.
Our data are in agreement with previous reports. In fact, miR-222 has been found to be upregulated in 10 different myopathies: a study by Eisenberg et al. [31] reported that a large number of miRs were differentially expressed in various muscular pathologies and, that, in particular, the expression of five miRs (miR-146b, miR-221, miR-155, miR-214, miR-222) was altered in all the analyzed syndromes. Recently, Greco et al. [32] , investigated miR expression in the adductor muscles from mdx mice and DMD bioptic samples, and miR-222 was among the eleven dysregulated miRs identified in that study. Together, these data indicated a potential role of miRs in dystrophy and our data confirmed the miR-222 upregulation in muscular dystrophy.
In addition, in agreement with a recent report by Cardinali et al. [39] , we also detected a reduction in miR-222 expression during myogenic differentiation of C 2 C 12 cells. These authors observed that in quails, murine primary muscle cells, and myogenic rodent cell lines, the miR-221/miR-222 cluster was highly expressed in proliferating myoblasts but downregulated in differentiated myotubes. The decreased expression of miR-222 during C 2 C 12 differentiation could explain the corresponding two-to three-fold increase in b1-syntrophin levels in differentiating versus proliferating C 2 C 12 cells [40] . Cardinali et al. showed that p27 acts as a direct target of miR-222, thus implying a prominent role of this miR in the myogenic process. In our study, we showed, for the first time, that the b1-syntrophin protein is a target of miR-222. Furthermore, overexpression of miR-222 in proliferating C 2 C 12 myogenic cells, induced a modulation of myogenic miRs suggesting a potential novel regulatory role of miR-222 in the differentiation process.
We demonstrated that miR-222 modulates the b1-syntrophin protein in the cells of different tissues. In muscle cells and the hepatic cell line Hep2, it was shown that endogenous b1-syntrophin protein levels were reduced after transfection with miR-222 and that the inhibitory effect of miR-222 was blocked in the presence of anti-miR-222, which then restored b1-syntrophin protein expression to normal. In satellite dystrophic cells expressing high levels of miR-222, anti-miR-222 treatment slightly increased b1-syntrophin protein levels. This experiment clearly indicates that the impairment of b1-syntrophin protein expression in dystrophic cells is due to the elevated levels of endogenous miR-222, and that b1-syntrophin protein levels can be restored by antimiR treatment.
In addition to its structural role, b1-syntrophin may also perform an important cell signaling role. In different tissues, several partners have been identified to bind b1-syntrophin, including the ATP binding cassette transporter A, the a1D adrenergic receptor isoform, the voltage-gated sodium channel Nav1.5 and, the potassium channel Kir2 [41] [42] [43] [44] [45] . Given its scaffold b1-syntrophin may play an important role in muscle diseases by regulating signaling complex localization. In particular, loss of b1-syntrophin could impair the function of ionic channels at specific sarcolemma regions, such as neuromuscular junctions. Indeed, b1-syntrophin is mainly localized on the sarcolemma of the type IIb-fast twitch muscle fibers, that are preferentially affected in DMD [34] , suggesting that the absence of b1-syntrophin could worsen the disease. Thus, a fine regulation of b1-syntrophin protein levels is necessary for it to exert proper signaling and mechanical roles, allowing for the appropriate cell function.
In conclusion, our results showed that in dystrophic muscle increased miR-222 expression lead to the decrease in b1-syntrophin expression by specifically binding to the 39-UTR of b1-syntrophin. A specific antagonist of miR-222 allow rescued b1-syntrophin protein expression in dystrophic satellite cells. These data demonstrate, for the first time, that miRs are involved in the regulation of the DAPC components in dystrophic muscles. The involvement of miRs in the pathophysiology of muscle diseases suggests that these molecules could serve as potential targets for a complementary novel therapeutic approach, because silencing miRs could enhance the expression of DAPC components.
Materials and Methods
Ethics statement
All procedures involving mice were completed in accordance with the Italian National Institute of Health (protocol n. 118/99-A) and the ethical guidelines for animal care of the European Community Council (directive 86/609/ECC).
C57BL/6J mice and mdx mice were obtained from the Charles River Laboratories Italia s.r.l. (Calco, Lecco, Italy) and were housed in the animal facility of the Department of Histology and Medical Embryology under a 12-h light-dark schedule at a constant temperature and with food and water ad libitum. Animals were sacrificed by carbon dioxide asphyxiation. To minimize unnecessary suffering, before gene delivery into tibialis muscles, the mice were anesthetized by an intra-peritoneal injection of a solution of 80 to100 mg/kg ketamine (Intravet, Italy) +10 mg/kg xylazine (Sigma-Aldrich, St. Louis, MO, USA).
After the animals were sacrified, skeletal muscle tissues were collected and divided into three pieces: two were frozen in liquid nitrogen for RNA and protein extractions, and one was frozen in liquid nitrogen cooled isopentan, for immunological studies. All samples were stored at 280uC.
Database analysis
We used the target prediction programs: the Miranda package and targetscan, available at the following website location: http:// microrna.sanger.ac.uk; http://www.targetscan.org; http://www. microrna.org.
RNA preparation and analysis
RNA was isolated from muscle tissue samples of wt and mdx mice of different ages. Four different RNA samples were prepared, each from tissue pools obtained by combining muscles from multiple mice (n = 6, 20-day-old, n = 2, 30-day-old, n = 2, fivemonth-old wt mice; n = 8, 20-day-old, n = 4, 30-day-old, n = 2, five-month-old mdx mice). Total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbard, CA, USA) according to the manufacturer's instructions. RNA expression was determined by northern blot analysis and/or qRT-PCR [46] . Northern blot was performed using 30 mg of total RNA that was separated on a 15% denaturing polyacrylamide gel and transferred from the gel to a Hybond-N + membrane (Amersham Biosciences/GE Healthcare, Piscataway, NJ). Blotted membranes were fixed by UV crosslinking and heating at 80uC for 1 h, and processed for hybridization. Hybridization was carried out overnight at 38uC in a hybridization buffer containing 5X SSC [20X SSC: 3M NaCl, 0.3 M NaCitrate], 20 mM Na 2 HPO 4 pH 7.2, 7% SDS, 50% formamide, 50 mg/ml salmon sperm DNA and 10 6 cpm/ml of radiolabed probe. The probes were oligonucleotides synthesized on the basis of sequences complementary to the corresponding miR (see Table 1 ) and labelled at the 59end with 32 P-cATP. Membranes were washed in 5X SSC and 0.2% SDS at 37uC and 2X SSC and 0.2% SDS at 37uC and then exposed to a Fuji phosphoimager screen. Detection was performed using a phosphoimager after an overnight exposure. The same filters were then hybridized with a U6 probe to normalize the RNA levels for quantitative analysis with a densitometer.
Quantitative real-time RT-PCR was performed using the DyNAmo SYBR Green 2-step qRT-PCR kit (Finnzymes, Kellaranta, Finland) or the TaqMan MicroRNA Assay kit (Ambion/Applied Biosystem, Piscataway, NJ, USA) according to the protocol for use in the Applied Biosystems 7500 Fast RealTime PCR System. For quantification analysis the comparative threshold cycle (Ct) method was used. The Ct values of each gene were normalized to the Ct value of GAPDH or Sno142 in the same RNA sample. Gene expression levels were evaluated as fold change using the equation 2 2ddCt . The primers used are reported in Table 1 .
Vector constructs
The 39-UTR of b1-syntrophin was synthesized by RT-PCR. The mRNA sequence of b1-syntrophin was retrieved from GenBank (U89997). Based on this sequence, oligonucleotide couples flanking the 39-UTR were designed, synthesized and used as primers for RT-PCR. The PCR product was cloned into a PCR-TOPO vector (InVitrogen, Carlsbard, CA, USA), sequenced and, subsequently, subcloned into a luciferase reporter plasmid, pGL3basic (Promega, Madison, WI, USA) for luciferase assay. The same 39-UTR DNA fragment was miR-222 in mdx subcloned into pEGFP-C (Clontech, Takara Bio USA, CA, USA) at the 39-end of the EGFP construct in which GFP expression is driven by the CMV promoter. Mutations in the 39-UTR of b1-syntrophin, were introduced using the Quick Change site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Oligonucleotide primers for cloning and mutagenesis are listed in Table 1 .
Cell culture, transfection and luciferase assays
Transfection was performed using the Lipofectamine 2000 reagent (InVitrogen; Carlsbard, CA, USA) according to the manufacturer's protocol.
To assess luciferase activity, COS-1 cells (ATCC, CRL-1650) were cultured in DMEM supplemented with 10% fetal calf serum. One day prior to the transfection, the cells were plated onto 12-well plates at a density of 80,000/well. The next day, the cells were co-transfected with 1 mg of the pGL3 constructs, and appropriate amounts of miR (Ambion/Applied Biosystem, Piscataway, NJ, USA) and Lipofectamine 2000. The cells were cultured for 4 h in DMEM without serum or antibiotics. Afterwards, the medium was changed, and the cells were incubated in medium supplemented with serum. After 24 h, the cells were collected and homogenized in 70 ml of lysis buffer (Promega, Madison, WI, USA). The cell lysates were centrifuged for 5 min at 12,000 g. Luciferase activity was detected using the luciferase reporter assay system (Promega) and measured by a luminometer. Protein concentration was determined by the BCA assay (Pierce/Thermo Scientific, Rockford, IL, USA).
For western blot analysis, the cells were plated at a density of 70,000/well and transfected either with or without 5610
28 M miR-222 or antimiR-222 (Ambion/Applied Biosystem, Piscataway, NJ, USA). After an incubation of 4 h in medium without serum or antibiotics, the cells were incubated for another 36 h in medium supplemented with serum. At the end of the incubation time, the cells were collected and homogenized in 70 ml of Laemmli buffer. The following cell lines were used: C 2 C 12 (ATCC, CRL-1772) and Hep2 (ATCC, CCL-23).
In another series of experiments, C 2 C 12 cells were transfected with miR-222 or antimiR-222 and the expression levels of miR-1, miR-133, miR-206 were measured. One day prior the transfection, the cells were plated at a density of 10,000/cm 2 . The next day the cells were co-transfected with 5610
28 M miR or antimiR (Ambion/Applied Biosystem, Piscataway, NJ, USA) and Lipofectamine 2000. The cells were cultured for 4 h in DMEM without serum or antibiotics. Afterwards, the medium was changed, and the cells were incubated in medium supplemented with serum. After 24 h, the cells were collected, and RNA was prepared using the Trizol reagent as indicated above.
Primary cell cultures
Primary cell cultures were performed according to Matthew et al. [47] . Briefly, dissected muscles from five to six one-week-old animals (n = 20 wt and 24 mdx mice in total) were minced by a razor blade and then digested by collagenase/dispase. The resulting cellular suspension was plated for a few hours to remove contaminating fibroblasts, and the unattached muscle cells were collected and plated on collagene-coated dishes in DMEM (Gibco/InVitrogen, Carlsbard, CA, USA) supplemented with 10% serum. The cultured cells were later processed for transfection experiments and western blot analysis.
Protein analyses
Frozen muscle tissue samples from wt and mdx mice were homogenized in lysis buffer (2% SDS, 5 mM EDTA) supplemented with proteinase inhibitors, boiled for 5 minutes and centrifuged at 12,000 g for 10 min [48] . Protein concentration was determined by the BCA assay (Pierce/Thermo Scientific, Rockford, IL, USA). For each preparation multiple muscle tissues were pooled (n = 2, 30-day-old and n = 1 wt 5-month-old wt mice; n = 3, 30-day-old and n = 1, 5 month-old mdx mice.)
Protein aliquots ranging from 30-40 mg were separated by electrophoresis on a 10% SDS-acrylamide gel and transferred onto a nitrocellulose membrane. The blotted membranes were blocked in TBS-T (20 mM Tris-HCl pH 7.5, 137 mM NaCl, and Immunoprecipitation analyses were performed following a standard protocol as previously described [49] . Muscle tissue fragments from young and adult wt and mdx mice were lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% deoxycholate, and 0.1% SDS) and aliquots containing 1 mg of protein extracts were incubated overnight at 4uC with an antibody anti a-b-syntrophins (Affinity Bioreagents, Golden, CO, USA). The protein-antibody complex was recovered by incubation with protein G-sepharose, separated on SDS-PAGE and probed with an anti-b1-syntrophin antibody.
To determine the localization of different proteins, immunofluorescence analysis, was performed as documented [50] . 7 mm sections were prepared from frozen muscles, permeabilized with 0.1% Triton-X-100, blocked with 5% BSA-TBS-T and incubated with primary antibodies. The specific proteins were visualized using secondary antibodies coupled to a fluorescent marker (fluorescein isothiocyanate, FITC or Texas red; Pierce, Thermoscientific, Rockford, Il, USA). Immunostained samples were counterstained with DAPI (49,69-diamidino-2-phenylindole dihydrochloride: Molecular Probes, Eugene, OR) and examined by a Zeiss Axioskop2 plus microscope. Images were obtained with a Zeiss AxioCam HRc using the Axiovision software.
The following antibodies were used: a-dystroglycan clone VIA4-1 (Millipore, Billerica, MA, USA), b-dystroglycan clone 43DAG1/8D5 (Monosan, Uden, NL), a-syntrophin RA16-1 (Sigma-Aldrich, St. Louis, MO, USA), b1-syntrophin clone C20 (SantaCruz Biotechnology, Santa Cruz, CA, USA).
For this analysis, a total of n = 3 wt mice and n = 3 mdx adult mice were used.
Gene delivery into tibialis muscles
In vivo experiments were performed on 30-days-old wt (n = 3) and mdx mice (n = 5) or 5-month-old mdx mice (n = 2) [51] . Tibialis anterior muscles were exposed using a short incision and 20 ml of a solution of 5% mannitol containing 20 mg of DNA (pEGPF2C1 or pEGFP-39UTR-b1-synt) was injected using a Hamilton syringe in the central part of the muscle. One leg received the empty vector pEGPF-C1, the other the pEGFP-39UTR-b1-synt construct. Afterwards, the muscle was separated from tibia, and a pair of spatula-like electrodes (0.5 cm wide, 2 cm long) were placed at each side of the muscle close to the injection site (anode was positioned under the muscle in transverse direction relative to the fibers, and cathode was placed on the muscle in longitudinal direction) and electric pulses were delivered. Six electric pulses with the fixed pulse duration of 50 msec/pulse, were delivered at an interval of 200 ms using an electric pulse generator. The ratio of applied voltage to electrode distance was 5V/mm (muscle thickness). Mice were sacrificed 24 h after the electroporation and muscles were removed, frozen in liquid nitrogen-cooled isopentan, and then processed for morphological analysis.
Several 7-mm thick cryostat sections, upstream and downstream of the injection site were prepared, GFP expression was examined using a Zeiss Axioskop2 plus fluorescence microscope (Carl Zeiss, Oberkochen, Germany). As a control for gene delivery, PCR and RT-PCR analyses were performed on genomic and RNA samples, respectively. Oligonucleotide primers for GFP are listed in Table 1 .
Statistical analysis
Data are presented as mean 6 standard deviation (SD) or standard error (SE). Statistical significance between groups was determined using the GraphPad Prism software. The non parametric-Mann-Whitney test was done for the analysis of RNA expression, protein expression and luciferase activity when sample groups were small. The unpaired t-test was performed to assess the significativity of gene delivery experiments. P values of less than 0.05 were considered statistically significant. 
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